Role of cannabinoids in multiple sclerosis

CNS Drugs

Volumn 25, Issue 3, 2011, Pages 187-201

  Zajicek, John P ^a   Apostu, Vicentiu I ^a  

^a PENINSULA MEDICAL SCHOOL   (United Kingdom)

Author keywords

Cannabinoids, therapeutic use; Dronabinol, therapeutic use; Multiple sclerosis; Nabilone, therapeutic use; Tetrahydrocannabinolcannabidiol, therapeutic use

Indexed keywords

AMITRIPTYLINE; ANALGESIC AGENT; BACLOFEN; BENZODIAZEPINE DERIVATIVE; BETA ADRENERGIC RECEPTOR BLOCKING AGENT; BOTULINUM TOXIN; BUSPIRONE; CANNABIDIOL; CANNABINOID; CANNABINOID RECEPTOR; CANNABIS; CARBAMAZEPINE; CLONAZEPAM; DESMOPRESSIN; DRONABINOL; ENDOCANNABINOID; ETIRACETAM; GABAPENTIN; ISONIAZID; LAMOTRIGINE; NABILONE; NONSTEROID ANTIINFLAMMATORY AGENT; OXCARBAZEPINE; OXYBUTYNIN; PLACEBO; PREGABALIN; PRIMIDONE; TIZANIDINE; TOLTERODINE; UNINDEXED DRUG;

ALLERGIC ENCEPHALOMYELITIS; ASHWORTH SCALE; ATAXIA; CONTROLLED CLINICAL TRIAL (TOPIC); DISEASE COURSE; DRUG DOSE TITRATION; DRUG RECEPTOR BINDING; DRUG SAFETY; DRUG TOLERABILITY; EVENING DOSAGE; HUMAN; INFLAMMATION; LOW DRUG DOSE; MICTURITION DISORDER; MULTICENTER STUDY (TOPIC); MULTIPLE SCLEROSIS; NEUROPROTECTION; NOCTURIA; NONHUMAN; NYSTAGMUS; OVERACTIVE BLADDER; PAIN; PHYSIOTHERAPY; PRIORITY JOURNAL; RANDOMIZED CONTROLLED TRIAL (TOPIC); RATING SCALE; REVIEW; SEDATION; SIDE EFFECT; SINGLE DRUG DOSE; SPASTICITY; TREMOR; UNSPECIFIED SIDE EFFECT;

ANIMALS; CANNABINOIDS; CANNABIS; CLINICAL TRIALS AS TOPIC; ENDOCANNABINOIDS; HUMANS; MULTIPLE SCLEROSIS; RECEPTORS, CANNABINOID;

EID: 79951751577     PISSN: 11727047     EISSN: 11791934     Source Type: Journal    
DOI: 10.2165/11539000-000000000-00000     Document Type: Review

References (107)

1. Mahlberg PG, Kim ES. Secretory vesicle formation in glandular trichomes of Cannabis sativa L. (Cannaba-ceae). Am J Bot 1992; 79: 166-73.
2. Work TS, Bergel F, Todd AR. The active principles of Cannabis indica resin: I. Biochem J 1939 Jan; 33 (1): 123-7.
3. Adams R, Pease DC, Cain CK, et al. Conversion of cannabi-diol to a product with marihuana activity: a type reaction for synthesis of analogous substances: conversion of cannabidiol to cannabinol. J Am Chem Soc 1940; 62 (8): 2245-6.
4. Ghosh R, Todd AR, Wilkinson S. Cannabis indica, part IV: the synthesis of some tetrahydrodibenzopyran derivatives. J Chem Soc 1940; 1121-5.
5. Adams R, Baker BR. Structure of cannabinol, V: a second method of synthesis of cannabinol. J Am Chem Soc 1940; 62 (9): 2401.
6. Gaoni Y, Mechoulam R. Isolation, structure and partial synthesis of an active constituent of hashish. J Am Chem Soc 1964; 86: 1646-7.
7. Mechoulam R, Shvo Y. The structure of cannabidiol. Tetrahedron 1963; 19: 2073-8.
8. Matsuda LA, Lolait SJ, Brownstein MJ, et al. Structure of a cannabinoid receptor and functional expression of the cloned cDNA. Nature 1990; 346: 561-4.
9. Munro S, Thomas KL, Abu-Shaar M. Molecular char-acterization of a peripheral receptor for cannabinoids. Nature 1993; 365: 61-5. (Pubitemid 23305569)
10. Ryberg E, Larsson N, Sjogren S, et al. The orphan receptor GPR55 is a novel cannabinoid receptor. Br J Pharmacol 2007; 152: 984-6.
11. Pertwee R. Cannabinoid receptors and pain. Prog Neurobiol 2001; 63: 569-611. (Pubitemid 32115433)
12. Begg M, Dale N, Llaudet E, et al. Modulation of the release of endogenous adenosine by cannabinoids in the myen-teric plexus-longitudinal muscle preparation of the guinea-pig ileum. Br J Pharmacol 2002 Dec; 137 (8): 1298-304. (Pubitemid 36071747)
13. Howlett AC, Barth F, Bonner TI, et al. International Union of Pharmacology, XXVII: classification of cannabinoid receptors. Pharmacol Rev 2002; 54: 161-202.
14. Glass M, Faull RL, Dragunow M. Cannabinoid receptors in the human brain: a detailed anatomical and quantitative autoradiographic study in the fetal, neonatal and adult human brain. Neuroscience 1997; 77 (2): 299-318. (Pubitemid 27079604)
15. Galiegue S, Mary S, Marchand J, et al. Expression of central and peripheral cannabinoid receptors in human immune tissues and leukocyte subpopulations. Eur J Biochem 1995 Aug 15; 232 (1): 54-61.
16. Devane WA, Hanus L, Breuer A, et al. Isolation and structure of a brain constituent that binds to the canna-binoid receptor. Science 1992 Dec 18; 258 (5090): 1946-9. (Pubitemid 23026736)
17. Mechoulam R, Ben-Shabat S, Hanus L, et al. Identification of an endogenous 2-monoglyceride, present in canine gut, that binds to cannabinoid receptors. Biochem Pharmacol 1995; 50: 83-90.
18. Sugiura T, Kondo S, Sukagawa A, et al. 2-Arachido-noylglycerol: a possible endogenous cannabinoid receptor ligand in brain. Biochem Biophys Res Commun 1995; 215: 89-97.
19. Jhaveri MD, Richardson D, Chapman V. Endocanna-binoid metabolism and uptake: novel targets for neuropathic and inflammatory pain. Br J Pharmacol 2007; 152: 624-32. (Pubitemid 350034979)
20. Bohme GA, Laville M, Ledent C, et al. Enhanced long-term potentiation in mice lacking cannabinoid CB1 receptors. Neuroscience 2000; 95: 5-7.
21. Reibaud M, Obinu MC, Ledent C, et al. Enhancement of memory in cannabinoid CB1 receptor knock-out mice. Eur J Pharmacol 1999; 379: R1-2. (Pubitemid 29492956)
22. Zimmer A, Zimmer AM, Hohmann AG, et al. Increased mortality, hypoactivity, and hypoalgesia in cannabinoid CB1 receptor knockout mice. Proc Natl Acad Sci USA 1999 May 11; 96 (10): 5780-5. (Pubitemid 29234695)
23. Ledent C, Valverde O, Cossu G, et al. Unresponsiveness to cannabinoids and reduced addictive effects of opiates in CB1 receptor knockout mice. Science 1999; 283: 401-4.
24. Di Marzo V, Goparaju SK, Wang L, et al. Leptin-regulated endocannabinoids are involved in maintaining food intake. Nature (London) 2001 Apr 12; 410: 822-5. (Pubitemid 32303781)
25. Louw DF, Yang FW, Sutherland GR. The effect of delta-9- tetrahydrocannabinol on forebrain ischemia in rat. Brain Res 2000 Feb 28; 857 (1-2): 183-7. (Pubitemid 30107804)
26. Zhang M, Martin RB, Adler WM, et al. Modulation of cannabinoid receptor activation as a neuroprotective strategy for EAE and stroke. J Neuroimm Pharmacol 2009 Jun; 4 (2): 249-59.
27. Maresz K, Pryce G, Ponomarev ED, et al. Direct suppression of CNS autoimmune inflammation via the cannabi-noid receptor CB1 on neurons and CB2 on autoreactive T cells. Nat Med 2007 Apr; 13 (4): 492-7. (Pubitemid 46559830)
28. Pryce G, Ahmed Z, Hankey DJ, et al. Cannabinoids inhibit neurodegeneration in models of multiple sclerosis. Brain 2003 Oct; 126 (Pt 10): 2191-202. (Pubitemid 37432364)
29. Palazuelos J, Aguado T, Pazos MR, et al. Microglial CB2 cannabinoid receptors are neuroprotective in Hunting-ton's disease excitotoxicity. Brain 2009 Nov; 132 (Pt 11): 3152-64.
30. Hampson AJ, Grimaldi M, Axelrod J, et al. Cannabidiol and (-)delta9-tetrahydrocannabinol are neuroprotective antioxidants. Proc Natl Acad Sci USA 1998; 95: 8268-73. (Pubitemid 28326102)
31. Kreitzer AC, Regehr WG. Retrograde inhibition of pre-synaptic calcium influx by endogenous cannabinoids at excitatory synapses on to Purkinje cells. Neuron 2001; 29: 717-27. (Pubitemid 32323944)
32. Twitchell W, Brown S, Mackie K. Cannabinoids inhibit N-and P/Q-type calcium channels in cultured rat hippocampal neurons. J Neurophysiol 1997; 78: 43-50. (Pubitemid 27318909)
33. Molina-Holgado E, Vela JM, Arevalo-Martin A, et al. Cannabinoids promote oligodendrocyte progenitor survival: involvement of cannabinoid receptors and phos-phatidylinositol-3 kinase/Akt signaling. J Neurosci 2002 Nov 15; 22 (22): 9742-53. (Pubitemid 35332857)
34. Arevalo-Martin A, Vela JM, Molina-Holgado E, et al. Therapeutic action of cannabinoids in a murine model of multiple sclerosis. J Neurosci. 2003 Apr 1; 23: 7: 2511-6.
35. van Oosten BW, Killestein J, Mathus-Vliegen EM, et al. Multiple sclerosis following treatment with a cannabinoid receptor-1 antagonist. Mult Scler 2004 Jun; 10 (3): 330-1. (Pubitemid 38807464)
36. UNODC United Nations Office on Drugs and Crime). Why should we care about cannabis? [online]. Available from URL: http://www.unodc.org/unodc/en/ frontpage/why-should-we-care-about-cannabis.html [Accessed 2010 Oct 10].
37. Zajicek J, Freeman, Porter B. Multiple sclerosis care: a practical manual. Oxford: Oxford University Press, 2007: 164.
38. Clark AJ, Ware MA, Yazer E, et al. Patterns of cannabis use among patients with multiple sclerosis. Neurology 2004 Jun 8; 62 (11): 2098-100. (Pubitemid 38738230)
39. Page SA, Verhoef MJ, Stebbins RA, et al. Cannabis use as described by people with multiple sclerosis. Can J Neurol Sci 2003 Aug; 30 (3): 201-5. (Pubitemid 37064512)
40. Baker D, Pryce G. The endocannabinoid system and mul-tiple sclerosis. Curr Pharm Des 2008; 14: 23: 2326-36.
41. Hosking RD, Zajicek JP. Therapeutic potential of cannabis in pain medicine. Br J Anaesth 2008 Jul; 101 (1): 59-68. (Pubitemid 351881914)
42. Pertwee RG. Emerging strategies for exploiting cannabi-noid receptor agonists as medicines. Br J Pharmacol 2009 Feb; 156 (3): 397-411.
43. Medicines and Healthcare products Regulatory Agency. Public assessment report [online]. Available from URL: http://www.mhra.gov.uk/home/groups/par/ documents/web siteresources/con084961.pdf [Accessed 2011 Jan 4].
44. McGilveray IJ. Pharmacokinetics of cannabinoids. Pain Res Manage 2005; 10 Suppl. A: 15A-22A. (Pubitemid 44796349)
45. Huestis MA. Pharmacokinetics and metabolism of the plant cannabinoids, delta9-tetrahydrocannabinol, canna-bidiol and cannabinol. Handb Exp Pharmacol 2005; (168): 657-90.
46. McDonald WI, Compston A, Edan G, et al. Recommend-ed diagnostic criteria for multiple sclerosis: guidelines from the International Panel on the diagnosis of multiple sclerosis. Ann Neurol 2001 Jul; 50 (1): 121-7.
47. Consroe P, Musty R, Rein J, et al. The perceived effects of smoked cannabis on patients with multiple sclerosis. Eur Neurol 1997; 38 (1): 44-8. (Pubitemid 27283078)
48. Heltberg A. A double-blind trial with baclofen (Lioresal) and diazepam in spasticity due to multiple sclerosis. Acta Neurol Scand 1975; 51: 158-66.
49. Cartlidge NE, Hudgson P, Weightman D. A comparison of baclofen and diazepam in the treatment of spasticity. J Neurol Sci 1974; 23: 17-24.
50. A double-blind, placebocontrolled trial of tizanidine in the treatment of spasticity caused by multiple sclerosis: United Kingdom Tizanidine Trial Group. Neurology 1994; 44 (11 Suppl. 9): S70-8.
51. Smith C, Birnbaum G, Carter JL, et al. Tizanidine treat-ment of spasticity caused by multiple sclerosis: results of a doubleblind, placebocontrolled trial. US Tizanidine Study Group. Neurology 1994; 44 (11 Suppl. 9): S34-42.
52. Cutter NC, Scott DD, Johnson JC, et al. Gabapentin effect on spasticity in multiple sclerosis: a placebocontrolled, randomized trial. Arch Phys Med Rehabil 2000 Feb; 81 (2): 164-9. (Pubitemid 30080673)
53. Petro DJ, Ellenberger Jr C. Treatment of human spasticity with delta 9-tetrahydrocannabinol. J Clin Pharmacol 1981 Aug-Sep; 21 (8-9 Suppl.): 413S-6S.
54. Ungerleider JT, Andyrsiak T, Fairbanks L, et al. Delta-9-THC in the treatment of spasticity associated with multiple sclerosis. Adv Alcohol Subst Abuse 1987; 7 (1): 39-50.
55. Killestein J, Hoogervorst EL, Reif M, et al. Safety, toler-ability and efficacy of orally administered cannabinoids in MS. Neurology 2002 May 14; 58 (9): 1404-7. (Pubitemid 34507170)
56. Zajicek J, Fox P, Sanders H, et al. Cannabinoids for treat-ment of spasticity and other symptoms related to multiple sclerosis (CAMS study): multicentre randomised placebocontrolled trial. Lancet 2003 Nov 8; 362 (9395): 1517-26. (Pubitemid 37410189)
57. Zajicek JP, Sanders HP, Wright DE, et al. Cannabinoids in Multiple Sclerosis (CAMS) study: safety and efficacy data for 12 months follow up. J Neurol Neurosurg Psychiatry 2005 Dec; 76 (12): 1664-9. (Pubitemid 41697631)
58. Vaney C, Heinzel-Gutenbrunner M, Jobin P, et al. Effi-cacy, safety and tolerability of an orally administered cannabis extract in the treatment of spasticity in patients with multiple sclerosis: a randomized, double-blind, placebocontrolled, crossover study. Mult Scler 2004 Aug; 10 (4): 417-24. (Pubitemid 39117339)
59. Zajicek J, Reif M, Schnelle M. Cannabis extract in the treatment of muscle stiffness and other symptoms in multiple sclerosis: results of the MUSEC study [abstract no. P881]. Mult Scler 2009; 15: S274.
60. Wade DT, Makela P, Robson P, et al. Do cannabis-based medicinal extracts have general or specific effects on symptoms in multiple sclerosis? A double-blind, randomized, placebocontrolled study on 160 patients. Mult Scler 2004 Aug; 10 (4): 434-41. (Pubitemid 39117341)
61. Collin C, Davies P, Mutiboko IK, et al., Sativex Spasticity in MS Study Group. Randomized controlled trial of cannabis-based medicine in spasticity caused by multiple sclerosis. Eur J Neurol 2007 Mar; 14 (3): 290-6. (Pubitemid 46384865)
62. Ambler Z, Davies P, Gasperini C, et al. A twophase study of Sativex in the relief of spasticity due to multiple sclerosis: phase A single-blind response assessment followed by phase B double-blind, randomised, placebocontrolled, parallel-group study [abstract no. P844]. Mult Scler Sep 2009; 15: S258.
63. Wissel J, Haydn T, Muller J, et al. Low dose treatment with the synthetic cannabinoid nabilone significantly reduces spasticity-related pain: a double-blind placebocontrolled crossover trial. J Neurol 2006 Oct; 253 (10): 1337-41. (Pubitemid 44691559)
64. Freeman RM, Adekanmi O, Waterfield MR, et al. The ef-fect of cannabis on urge incontinence in patients with multiple sclerosis: a multicentre, randomised placebocontrolled trial (CAMS-LUTS). Int Urogynecol J Pelvic Floor Dysfunct 2006 Nov; 17 (6): 636-41. (Pubitemid 44575283)
65. Fox P, Bain PG, Glickman S, et al. The effect of cannabis on tremor in patients with multiple sclerosis. Neurology 2004 Apr 13; 62 (7): 1105-9. (Pubitemid 38456503)
66. Svendsen KB, Jensen TS, Bach FW. Does the cannabinoid dronabinol reduce central pain in multiple sclerosis? A randomised double blind placebo controlled crossover trial. BMJ 2004 Jul 31; 329 (7460): 253.
67. Notcutt W, Price M, Miller R, et al. Initial experiences with medicinal extractsofcannabis for chronic pain: results from 34 'N of 1' studies. Anaesthesia 2004 May; 59 (5): 440-52. (Pubitemid 38578684)
68. Rog DJ, Nurmikko TJ, Friede T, et al. Randomized, con-trolled trial of cannabis-based medicine in central pain in multiple sclerosis. Neurology 2005 Sep 27; 65 (6): 812-9. (Pubitemid 41362120)
69. Gross RA, Johnston KC. Levels of evidence: taking neurology to the next level. Neurology 2009; 72: 8-10.
70. Wilner AN. Lost in a jungle of evidence: we need a com-pass. Practice parameters and technology assessments -what they are, what they are not, and why you should care [letter]. Neurology 2009 Oct 20; 73 (16): 1337; author reply 1337-8.
71. Pincus MM. Lost in a jungle of evidence: we need a com-pass [letter]. Neurology 2009 Oct 20; 73 (16): 1338; author reply 1338-9.
72. French J, Gronseth G. Lost in a jungle of evidence: we need a compass. Neurology 2008 Nov 11; 71 (20): 1634-8.
73. Fowler CJ, Panicker JN, Drake M et al. A UK consensus on the management of the bladder in multiple sclerosis. Postgrad Med J 2009; 85: 552-9.
74. Gajewski JB, Awad SA. Oxybutynin versus propantheline in patients with multiple sclerosis and detrusor hyper-reflexia. J Urol 1986 May; 135 (5): 966-8. (Pubitemid 16077221)
75. Ethans KD, Nance PW, Bard RJ, et al. Efficacy and safety of tolterodine in people with neurogenic detrusor over-activity. J Spinal Cord Med 2004; 27 (3): 214-8. (Pubitemid 44210644)
76. Brady CM, DasGupta R, Dalton C, et al. An open-label pilot study of cannabis-based extracts for bladder dysfunction in advanced multiple sclerosis. Mult Scler 2004 Aug; 10 (4): 425-33. (Pubitemid 39117340)
77. Koller WC. Pharmacologic trials in the treatment of cere-bellar tremor. Arch Neurol 1984 Mar; 41 (3): 280-1. (Pubitemid 14198566)
78. Koch M, Mostert J, Heersema D, et al. Tremor in multiple sclerosis. J Neurol 2007 Feb; 254 (2): 133-45. (Pubitemid 46356045)
79. Charles PD, Esper GJ, Davis TL, et al. Classification of tremor and update on treatment. Am Fam Physician 1999 Mar 15; 59 (6): 1565-72. (Pubitemid 29168673)
80. Striano P, Coppola A, Vacca G, et al. Levetiracetam for cerebellar tremor in multiple sclerosis: an open-label pilot tolerability and efficacy study. J Neurol 2006 Jun; 253 (6): 762-6. (Pubitemid 43980148)
81. Feys P, D'hooghe M, Nagels G, et al. The effect of leve-tiracetam on tremor severity and functionality in patients with multiple sclerosis. Mult Scler 2009 Mar; 15 (3): 371-8.
82. Meinck HM, Schonle PW, Conrad B. Effect of cannabi-noids on spasticity and ataxia in multiple sclerosis. J Neurol 1989 Feb; 236 (2): 120-2. (Pubitemid 19110231)
83. Clifford DB. Tetrahydrocannabinol for tremor in multiple sclerosis. Ann Neurol 1983 Jun; 13 (6): 669-71. (Pubitemid 13103468)
84. Stahl JS, Rottach KG, Averbuch-Heller L, et al. A pilot study of gabapentin as treatment for acquired nystagmus. Neuroophthalmology 1996 Apr; 16 (2): 107-13.
85. Thurtell MJ, Joshi AC, Leone AC, et al. Crossover trial of gabapentin and memantine as treatment for acquired nystagmus. Ann Neurol 2010 May; 67 (5): 676-80.
86. Bandini F, Castello E, Mazzella L, et al. Gabapentin but not vigabatrin is effective in the treatment of acquired nystagmus in multiple sclerosis: how valid is the GABA-ergic hypothesis? J Neurol Neurosurg Psychiatry 2001 Jul; 71 (1): 107-10.
87. Schon F, Hart PE, Hodgson TL, et al. Suppression of pendular nystagmus by smoking cannabis in a patient with multiple sclerosis. Neurology 1999; 53: 2209-10.
88. Zajicek JP, Ingram WM, Vickery J, et al. Patient-orientated longitudinal study of multiple sclerosis in south west England (The South West Impact of Multiple Sclerosis Project, SWIMS) 1: protocol and baseline characteristics of cohort. BMC Neurol 2010 Oct 7; 10: 88.
89. Pollmann W, Feneberg W. Current management of pain associated with multiple sclerosis. CNS Drugs 2008; 22 (4): 291-324. (Pubitemid 351367440)
90. Brichetto G, Messmer Uccelli M, Mancardi GL, et al. Symptomatic medication use in multiple sclerosis. Mult Scler 2003 Oct; 9 (5): 458-60. (Pubitemid 37287723)
91. Solaro C. Epidemiology and treatment of pain in multiple sclerosis subjects. Neurol Sci 2006 Sep; 27 Suppl. 4: s291-3. (Pubitemid 44717576)
92. Breuer B, Pappagallo M, Knotkova H, et al. A randomized, double-blind, placebocontrolled, twoperiod, crossover, pilot trial of lamotrigine in patients with central pain due tomultiple sclerosis. Clin Ther 2007 Sep; 29 (9): 2022-30. (Pubitemid 350212812)
93. Silver M, Blum D, Grainger J, et al. Double-blind, placebo-controlled trial of lamotrigine in combination with other medications for neuropathic pain. J Pain Symptom Manage 2007 Oct; 34 (4): 446-54. (Pubitemid 47446144)
94. Solaro C, Brichetto G, Battaglia MA, et al. Antiepileptic medications in multiple sclerosis: adverse effects in a three-year follow-up study. Neurol Sci 2005 Feb; 25 (6): 307-10. (Pubitemid 40347907)
95. Solaro C, Uccelli MM, Guglieri P, et al. Gabapentin is ef-fective in treating nocturnal painful spasms in multiple sclerosis. Mult Scler 2000 Jun; 6 (3): 192-3. (Pubitemid 30392118)
96. Solaro C, Boehmker M, Tanganelli P. Pregabalin for treating paroxysmal painful symptoms in multiple sclerosis: a pilot study. J Neurol 2009 Oct; 256 (10): 1773-4.
97. Rossi S, Mataluni G, Codeca C, et al. Effects of levetir-acetam on chronic pain in multiple sclerosis: results of a pilot, randomized, placebocontrolled study. Eur J Neurol 2009 Mar; 16 (3): 360-6.
98. DMKG Study Group. Misoprostol in the treatment of trigeminal neuralgia associated with multiple sclerosis. J Neurol 2003 May; 250 (5): 542-5.
99. Rog DJ, Nurmikko TJ, Young CA. Oromucosal delta9-tetrahydrocannabinol/ cannabidiol for neuropathic pain associated with multiple sclerosis: an uncontrolled, open-label, 2-year extension trial. Clin Ther 2007 Sep; 29 (9): 2068-79. (Pubitemid 350218115)
100. Iskedjian M, Bereza B, Gordon A, et al. Meta-analysis of cannabis based treatments for neuropathic and multiple sclerosis-related pain. Curr Med Res Opin 2007 Jan; 23 (1): 17-24. (Pubitemid 46191666)
101. Greenberg HS, Werness SA, Pugh JE, et al. Short-term effects of smoking marijuana on balance in patients with multiple sclerosis and normal volunteers. Clin Pharmacol Ther 1994 Mar; 55 (3): 324-8. (Pubitemid 24183732)
102. Wade DT, Makela PM, House H, et al. Long-term use of a cannabis-based medicine in the treatment of spasticity and other symptoms in multiple sclerosis. Mult Scler 2006 Oct; 12 (5): 639-45. (Pubitemid 46940638)
103. Wang T, Collet JP, Shapiro S, et al. Adverse effects of medical cannabinoids: a systematic review. CMAJ 2008; 178 (13): 1669-78. (Pubitemid 351899653)
104. Papathanasopoulos P, Messinis L, Lyros E, et al. Multiple sclerosis, cannabinoids, and cognition. J Neuropsychiatr Clin Neurosci 2008 Dec; 20 (1): 36-51. (Pubitemid 351295027)
105. Langdon DW, Thompson AJ, Johnson KP, et al. The psychological effects of cannabis in MS: impact on cognition, pain, mood and fatigue [abstract]. Mult Scler ECTRIMS 2003; 9: S27.
106. Kurzthaler I, Bodner T, Kemmler G, et al. The effect of nabilone on neuropsychological functions related to driving ability: an extended case series. Hum Psychopharmacol 2005; 20: 291-3. (Pubitemid 40873467)
107. Hobart JC, Riazi A, Thompson AJ, et al. Getting the measure of spasticity in multiple sclerosis: the Multiple Sclerosis Spasticity Scale (MSSS-88). Brain 2006 Jan; 129 (Pt 1): 224-34 (Pubitemid 43063773)